key: cord-0712075-remostii
authors: Zhang, Wen; Qin, Chenman; Fei, Yunyun; Shen, Min; Zhou, Yangzhong; Zhang, Yan; Zeng, Xiaofeng; Zhang, Shuyang
title: Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
date: 2022-04-25
journal: Clin Immunol
DOI: 10.1016/j.clim.2022.109022
sha: 2763393b23a8908f60110c08cdba012aff4ea50d
doc_id: 712075
cord_uid: remostii

Last year in March, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and choloroquine/hydrocholoroquine.

One year ago, when the pandemic outbreak of coronavirus disease 2019 was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of

A number of studies and meta-analysis from different countries have reported many risk factors for COVID-19 to develop into a severe and critical stage, including old age, male gender, smoking, comorbidities (such as hypertension, diabetes, obesity, chronic lung disease, heart, liver and kidney disease and tumor), systemic or local immunodeficiency, and pregnancy. Laboratory parameters indicating deterioration include lymphopenia, significant increase in hypersensitive C-reactive protein (CRP), serum ferritin, and pro-inflammatory cytokines such as IL-6 and IL-1β, as well as increase in aspartate aminotransferase, lactate dehydrogenase, D-dimer and Krebs von den Lungen-6 (KL-6) and the activation of coagulation system [2] [3] [4] [5] .

The state of the body's immune system has important impact on the progression of COVID-19 to a severe and critical stage. Underlying immune states or immune-related treatments also have certain effects on the outcome of COVID-19.

Surveys in Chinese Hubei Province showed the risk of COVID-19 infection in rheumatic patients was 2.68 times higher than that in non-rheumatic patients [6] , and respiratory failure was more common in rheumatic patients infected with COVID-19 [7] . A study including 9 case series found that different anti-rheumatic medicines or biological agents for patients with autoimmune diseases had different influence on the course of the COVID-19. For example, patients treated with hydroxychloroquine or tumor necrosis factor α (TNFα) inhibitors had a relatively mild disease, while patients immunodeficiency (CVID), X-linked agammaglobulinemia due to loss-of-function mutations in the bruton tyrosine kinase (BTK), and 116 cases of acquired immunosuppression, who had been using immunosuppressant for a long time after heart, liver and kidney transplantation. The results showed that organ transplant recipients with COVID-19 had a higher mortality rate overall, which increased significantly with age, comorbidities, and complications. The mortality rate of kidney transplant recipients with COVID-19 was 0% for the <49-year age group; 20.8% for the 50-59-year age group, 12.5% for the 60-69-year age group, and up to 47.1% for the >70-year age group.

Cytokine storm is confirmed to be one of the important reasons for the worsening of COVID-19 patients. Several studies have found significant increase in cytokines in COVID-19 patients' serum, including IL-1, IL-1RA, IL-6, IL-7, IL-8, IL-9, IL-10, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), chemokine family (CXCL10, CCL2, CCL3), interferon-γ (IFN-γ), TNFα and vascular endothelial growth factor (VEGF) [10] [11] [12] , some of which were more significant in severe patients, such as IL-6, IL-10, IP-10, MCP-3 and macrophage inflammatory protein-1 (MIP-1) [10, 13] . Moreover, soluble IL-2 receptor (sCD25) was also significantly increased in most severe COVID-19 patients [11] . Elevated levels of ferritin and other inflammatory factors in peripheral blood also suggested that the activation of macrophage might be highly correlated with disease progression [11] .

The IL-6 released by activated macrophages is key to initiating cytokine storms hydroxychloroquine; 5) treatment which can directly remove inflammatory factors and toxins from patients' body, such as blood purification. Some of these clinical trials have been completed, which support or oppose their applications, but more clinical studies are still in progress.

Glucocorticoids have powerful anti-inflammatory action, which can inhibit inflammation caused by multiple causes. Glucocorticoids have been used in certain condition of viral pneumonia, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and influenza. Although some clinical trials have confirmed that glucocorticoids have a good effect on ARDS and sepsis [18] [19] [20] , it is still with controversy [21, 22] Working Group conducted a prospective meta-analysis, pooled data from 7 randomized clinical trials (RCT) to evaluate the efficacy of corticosteroids in 1,703 critically ill patients with COVID-19 (including 1,007 patients in RECOVERY study) [24] . 71% of patients were male and the median age was 60 years old, 1,459 patients received invasive mechanical ventilation. There were 425 deaths among 1025 patients randomized to usual care or placebo and 222 deaths among 678 patients randomized to glucocorticoids, suggesting that 28-day all-cause mortality of critically ill COVID-19 patients treated with glucocorticoids was lower than those treated with usual care or placebo (OR 0.66, 95% CI 0.53-0.82, P < 0.001). The study further analyzed the effect of glucocorticoids dose on mortality. The glucocorticoids dose was divided into high and low based on the cutoffs of 1 mg/kg/d of methylprednisolone, 15 mg/d of dexamethasone, 400 mg/d of hydrocortisone [19] . 28-day all-cause mortality in high dose group was lower than those with usual care or placebo (OR invasive mechanical ventilation). The overall safety of glucocorticoids therapy was good.

A systematic review and network meta-analysis of COVID-19 drugs [25] showed that mortality was lower in patients with glucocorticoids treatment than usual care Another systematic review and meta-analysis to evaluate the efficacy and safety of glucocorticoids in patients with COVID-19 included 37 retrospective studies, 5

RCTs, and 2 historical controlled studies with a total of 20,197 patients (median age 34-75 years) [26] . Results showed that for patients with moderate to severe respiratory failure, mortality was significantly reduced in glucocorticoids group (OR 0.72, 95% CI 0.57-0.87). Nasopharyngeal swabs were collected regularly for reverse transcription-polymerase chain reaction (RT-PCR) in 13 trials. As for the viral negative-transforming time, 9 trials showed prolonged in the glucocorticoid group, 2 trials showed prolonged in the usual care group, and 2 trials showed equal in 2 groups. 6 studies reported longer hospital stays in the glucocorticoid group and 5 reported longer stays in the usual care group, and 1 showed no difference in the 2 groups. 14 studies reported that glucocorticoid reduced the number of patients or the time of requiring mechanical ventilation. Of the 6 studies that reported infection, only 1 showed a lower rate of secondary infection in the glucocorticoid group [26] , while others showed a higher rate in the glucocorticoid group. 

Current evidence supports that early use of IL-6 receptor monoclonal antibody (tocilizumab) is beneficial for critically ill patients.

As mentioned above, serum IL-6 level is associated with the severity of COVID-19. The increasing level of IL-6 is predictive of the need for mechanical ventilation [31, 32] . Therefore, it is speculated that blocking the action of IL-6 may alter the course of the disease. A number of retrospective studies have suggested that tocilizumab might bring clinical improvement and survival benefit to patients with COVID-19, but the bias might exist. For the first time, a team from China retrospectively reviewed 21 patients with severe or critically ill COVID-19 treated with tocilizumab (4-8 mg/kg) and repeated use of tocilizumab if body temperature did not return to normal within 12 hours. The results showed that all patients' body temperature returned to normal on the day of treatment, and symptoms and imaging findings improved over the next few days [33] . Since then, most retrospective studies have shown that the use of tocilizumab might reduce the risk of intubation and/or death. A meta-analysis reviewing 1,358 patients from 10 different studies found a 12% reduction (95% CI 4.6%-20%) in the risk of death in the tocilizumab group [34] .

The largest retrospective study for critically ill patients to date included 3,924 ICU patients from 68 US hospitals, 40% of whom required mechanical ventilation support, and 433(11%) received tocilizumab (dose unknown) in the first 2 days of intensive J o u r n a l P r e -p r o o f Journal Pre-proof care unit (ICU) admission. After applying inverse probability weighting, it is found that mortality rate was significantly reduced in the tocilizumab group (HR 0.71, 95% CI 0.56-0.92) [35] , and no increase in the risk of secondary infection was observed. In a retrospective study of 154 patients using mechanical ventilation (median follow-up 47 days), the inverse probability weighted model showed a 45% reduction in the risk of death in the tocilizumab group (HR 0.55, 95% CI 0.33-0.90). Meanwhile, the infection rates increased significantly in the tocilizumab group (54% vs. 26%, P < 0.001), but the mortality rate did not increase [36] .

A randomized, open-label controlled trial (CORIMUNO-TOCI-1) evaluated the efficacy of tocilizumab in patients receiving oxygen treatment (who had not yet received noninvasive or invasive mechanical ventilation). 64 patients in the tocilizumab group (8 mg/kg on Day 1 and Day 3, respectively) had a downward trend in the rate of using mechanical ventilation or death on Day 14, but with no significant difference (24% vs. 36%, HR 0.58, 95% CI 0.33-1.00). In this study, the use of dexamethasone was significantly higher in control group (19%) than in tocilizumab group (9%), which may diminish the efficacy difference between two groups [36] . In another study, tocilizumab (8 mg/kg, followed by a second dose after 12 hours) did not reduce the incidence of clinical worsening compared with standard treatment (28.3% vs. 27.0%). However, 22% of patients in the standard treatment group received tocilizumab as a rescue therapy after clinical worsening, possibly introducing bias in the assessment of efficacy between the two groups [38] . non-intubated patients with severe COVID-19 but in hyperinflammatory states. There was a downward trend in 28-day intubation rate or mortality in the tocilizumab group, but without statistical significance (10.6% vs. 12.5%, HR 0.83, 95% CI 0.38-1.81) [40] . However, the expected incidence of the end point (30% in the control group and 15% in the tocilizumab group) based on the designed sample size was significantly higher than the final results (12.5% in the control group and 10.6% in the tocilizumab group), so the sample size required for this study may be underestimated. In another randomized, controlled, double-blind trial (EMPACTA) including 389 inpatients with COVID-19 who were not receiving ventilator support, tocilizumab reduced progression to mechanical ventilation or death at 28 days (12.0% vs. 19.3%, HR 0.56, 95% CI 0.33-0.97), but did not reduce the overall mortality at 28 days (10.4% vs.

8.6%) [41] . treated with tocilizumab were more likely to be discharged within 28 days (57% vs. 50%, RR 1.22, 95% CI 1.12-1.33, P < 0.0001) [43] .

In summary, although the benefits and risks of tocilizumab treatment remain to be clarified, available evidences from prospective randomized controlled studies and retrospective studies on tocilizumab in COVID-19 patients have suggested that tocilizumab might be considered for early use in critically ill patients who require high-flow oxygen treatment or higher levels of respiratory support. .

Anakinra is a kind of human recombinant IL-1 receptor antagonist, which has been approved for treatment of rheumatoid arthritis, NLRP3 related autoinflammatory disease [44] , and severe cytokine release syndrome (CRS) mediated by chimeric antigen receptors-T cells (CAR-T cells) and macrophage activation syndrome/ secondary hemophagocytic lymphohistiocytosis (off-label use). Studies have shown that serum IL-1β is increased in patients with COVID-19 [45] . At present, evidence from some case series has suggested that anakinra might inhibit inflammation and improve prognosis in patients with COVID-19. hours, followed by 100mg subcutaneously once daily for 7 days. Clinical characteristics were similar between the two groups, but the case group had a lower mean body mass index, a longer duration of symptoms, a higher frequency of use of hydroxychloroquine, and a higher frequency of use of azithromycin. The primary outcome of ICU admission rates due to need of mechanical ventilation or death were 25% (13 patients) and 73% (32 patients) in the case group and control group, respectively (hazard ratio 0.22, 95% CI 0.11-0.41). However, due to the limitations of the study design and unmeasurable confounding factors, the clinical significance of the results is uncertain [46] .

A single-center retrospective cohort study in Italy included 29 COVID-19 patients treated with anakinra compared with 16 historical patients as control group.

All patients had moderate-to-severe ARDS requiring non-invasive ventilation and hyperinflammation (CRP ≥ 100 mg/L or ferritin ≥ 900 ng/ml). Anakinra was administered intravenously with a high dose of 5 mg/kg twice daily for a median of 9 days, followed by 100 mg twice daily for 3 consecutive days. Both groups were treated with hydroxychloroquine and lopinavir/ritonavir. The CRP level in the anakinra group decreased in the first few days after treatment, and the 21-day survival rate was higher than that in control group (90% and 56%, respectively, P = 0.009). 7 patients (24%) in the high-dose anakinra discontinued treatment due to adverse events (4 of bacteremia, 3 of elevated liver enzymes). A further seven patients received low-dose anakinra, 100 mg twice daily but discontinued treatment after 7 days due to lack of clinical or anti-inflammatory efficacy [47] .

NSAIDs are widely used in symptomatic treatment of fever and in anti-inflammatory treatment of rheumatic diseases. It remains controversial regarding usage of NSAIDs in treatment of COVID-19 patients, since little data is available in this area [51] .

NSAIDs are not widely used in COVID-19 treatment for various reasons. Firstly, large amount of evidence indicated that the most severe complications of COVID-19 include sepsis, cardiovascular and respiratory failure, especially in the elderly and people with comorbidities [52] . As NSAIDs are associated with cardiovascular adverse events like myocardial infarction, heart failure and stroke [53, 54] , this has limited the application of NSAIDs in COVID-19 treatment. Secondly, NSAIDs are associated with renal toxicity [55, 56] , which may be aggravated in COVID-19 patients who are dehydrated due to fever, gastrointestinal symptoms or dyspnea.

Thirdly, it is concerned that NSAIDs might lower the defense mechanism against virus [57, 58] . For example, in a large clinical trial, 889 subjects with respiratory infection were randomized into three groups: Paracetamol group, Ibuprofen group, and Combo group in which subjects were given both drugs. The ibuprofen group had higher rate of complications (such as periamygdalitis, sinusitis, meningitis, pneumonia, tympanitis, and progressive or refractory tympanitis) or clinical non-response compared to the Paracetamol group (20% vs. 12%, adjusted HR = 1.67) [59] . Further analysis of this phenomenon indicated that NSAIDs may delay inflammatory responses and relieve infection by inhibiting polymorphonuclear cell recruitment in bacterial pneumonia [60, 61] . The most crucial reason, is that studies have found NSAIDs could upregulate angiotension converting enzyme 2 (ACE2) levels in target human cells [62] , and SARS-CoV-2 infects human lungs and other organs by binding ACE2 [63] [64] [65] , andACE2 expression is positively related to the risk J o u r n a l P r e -p r o o f Journal Pre-proof of coronavirus infections [66] , there is possibility that NSAIDs may aggravate COVID-19 patients' conditions. Therefore, many healthcare organizations, including FDA, EMA and WHO, recommended that although no correlation has been found between NSAIDs and clinical exacerbation of COVID-19, application of NSAIDs in COVID-19 patient should be with cautious [65, 67, 68] . However, rheumatologists raised different opinions: Firstly, the anti-inflammatory effects of NSAIDs may help prevent lethal cytokine storms in COVID-19, as studies discovered that Ibuprofen could reduce IL-6 in human tissue and sputum. In addition, they suggested patients with chonic inflammatory arthropathy or active arthritis (eg. rheumatoid arthritis or spondiloarthritis) continue their regular NSAIDs unless further evidence is available [69] . 

At the beginning of COVID-19 pandemic, scientists discovered in in-vitro studies that Chloroquine (CQ) and Hydroxychloroquine (HCQ) can inhibit glycosylation of ACE2 receptors [77] and block SARS-CoV-2 transfer from primary endosomes to intracellular lysosomes, thus potentially preventing the release of viral genome [78] . In addition, HCQ and azithromycin are both zinc ionophore that could inhibit SARS-CoV-2 replication [79] . CQ and HCQ were once considered highly promising therapies against SARS-CoV-2. Clinical trials were conducted in many countries evaluating CQ and HCQ in COVID-19 treatment, and in some of these studies they were combined with azithromycin.

In March 2020, a single-arm retrospective study was conducted in France [80] , in which 20 COVID-19 patients were given HCQ (600 mg/d), 6 of them received azithromycin concurrently, and compared with 16 patients in the control group. In HCQ group, viral load has dropped in 50% of patients on Day 3 (P = 0.005), and 60% (P = 0.04), 65%(P = 0.006), 70%(P = 0.001)on D4, D5 and D6 respectively. Therefore, it was believed that HCQ could reduce viral load in COVID-19 patients. In addition, all of the 6 patients who received azithromycin and HCQ had a decline of viral load on D6 (P < 0.001), indicating synergistic effects of combination therapy with azithromycin and HCQ .

However, following studies from US [81] [82] [83] , UK [84] and Brazil [85, 86] In summary, no consistent data was generated from large retrospective observational studies regarding the benefits of CQ/HCQ alone or combination with azithromycin to COVID-19 patients. By contrast, many large randomized studies showed no statistically significant difference between adding standalone CQ/HCQ or combination with azithromycin to standard of care and the control group. It is not recommended to use CQ/HCQ alone therapy or combination with azithromycin for COVID-19 treatment.

Apart from the aforementioned anti-inflammatory therapies, various other immunological treatments have been tried during the past year, such as intravenous Studies have shown that high dose immunoglobulins (0.3-0.5g/kg.d for 3-5 days continuously) in early stage are effective for severe COVID-19 patients [87] [88] [89] .

Currently, a total of 52 trials have been registered globally on Clinical Trial Website regarding convalescent plasma therapy for COVID-19, of which 8 were completed and no results have been reported yet. Though FDA has granted emergency use authorization to convalescent plasma, evidence-based data supporting its efficacy and correct timing are still insufficient.

MSCs were considered for COVID-19 treatment for their potential effects in immune regulation, inhibition of cytokine storm, reducing pulmonary fibrosis, enhancing self-repair capacity of lung tissues and clearing bacteria [90] . The understanding about usage of MSCs and relevant products in COVID-19 treatment is still preliminary [91, 92] . More clinical trials are needed to evaluate its benefits regarding the right population, origins of MSCs, timing and dose protocal.

Interferon is a group of cytokines with antiviral properties. However, studies have shown no efficacy of either interferon-α or interferon-β in COVID-19 patients.

Moreover, interferon generated significant toxicity and side effects that outweighed its potential benefits [93] [94] [95] .

In conclusion, during one and half year's global pandemic of COVID-19, doctors and scientists from all over the world have carried out a large number of clinical trials while actively fighting the disease. A lot of important progresses have been made in immune-related treatments and anti-inflammatory therapy. With the widespread application of vaccination and more effective treatments, the pandemic will be overcome eventually, and severe patients will be more effectively controlled. 

The use of anti-inflammatory drugs in the treatment of people with severe corona virus disease 2019 (COVID-19): The experience of clinical immunologists from China

Risk factors for severe and critically ill COVID-19 patients: A review

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Clinical features of rheumatic patients infected with COVID-19 in Wuhan

COVID-19 in rheumatic disease patients on immunosuppressive agents, Semin. Arthritis and Rheum

Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports

Clinical features of patients infected with 2019 novel coronavirus in

Clinical and immunological features of severe and moderate coronavirus disease 2019

A new coronavirus associated with human respiratory disease in China

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation SyndromeLike Disease

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Is a "Cytokine Storm" Relevant to COVID-19?

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and

CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Drug treatments for covid-19: living systematic review and network meta-analysis

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial，

Medicines and Healthcare Products Regulatory Agency, Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals

Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Effective treatment of severe COVID-19 patients with tocilizumab

Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Tria

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Food and Drug Administration

The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Anakinra for severe forms of COVID-19: a cohort study

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Use of anakinra in severe COVID-19: A case report

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronary risks associated with diclofenac and other NSAIDs: an update

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

The invisible threat of non-steroidal anti-inflammatory drugs for kidney, Front Pediatr

Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis

Dysregulation of immune response in patients with COVID-19 in

COVID-19: consider cytokine storm syndromes and immunosuppression

Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial

Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patient

Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rat

Angiotensin converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines

Non-steroidal anti-inflammatory drugs and covid-19

Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)

Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Relevance of the Bruton Tyrosine Kinase (BTK) as a target for COVID-19 therapy

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state

Effect of hydroxychloroquine in hospitalized patients with COVID-19

Hydroxychloroquine with or without azithromycin in mild to moderate COVID-19

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial

Effect of regular intravenous immunoglobul in therapy on prognosis of severe pneumonia in patients with COVID-19

Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

Mesenchymal stromal cells for sepsis and septic shock: lessons for treatment of COVID-19

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, Phase 2 trial

Interferon-alpha2b treatment for COVID-19